Physician & entrepreneur with 30+ years of clinical experience. Gal-3 expert and inventor of Gal-3 inhibitor. Founder of Amitabha Apheresis Clinic, ecoNugenics (acquired in 2023 by a leading PE).
Multi-patent holder and published author.

Accomplished, senior accounting and financial management executive with more than 20 years of experience in the medical device, life science, and semiconductor industries.  Prior to finance, worked in product development as a chemical engineer.

Business development, strategy and operation veteran with 18 years' experience in healthcare and biotechnology. Managed ecoNugenics, a nutraceutical company specialising in Gal-3, for 7 years (resulting in a successful private equity acquisition in 2023).

With an MBA and 20+ years of experience in financial management, business development, and M&A, Bryan has scaled ventures across healthcare and medtech. He specializes in securing capital, go-to-market strategies, and fostering relationships for growth.

Expert in acute kidney failure and chronic kidney disease with more than 30 years of clinical experience. Dr. Chertow has conducted sponsored and NIH-funded trials throughout his career and maintained a research program devoted to improving kidney patient treatment.

Mr. Boone has over four decades of experience in protein therapeutics, including 28 years at Amgen, where he expanded the Protein Sciences division to more than 300 researchers across five sites. He assists with R&D activities and guides ETI through GMP manufacturing for clinical trials.

With 20 years in academia and biotech, he specialises in biochemistry, molecular biology, and product development optimization. His expertise in immunotherapy and neurodegenerative diseases, equips him to contribute valuable insights to ETI's sepsis-focused initiatives.